Skip to content
Companies

Cresilon

Plant-based gel that stops severe bleeding

Raised to date

$29M

of $29M offered across 2 Form D filings

Still open
$801
Investors
21
Last filed
Jun 26, 2026

About

Cresilon is a Brooklyn-based biotechnology company that develops, manufactures and markets hemostatic medical devices built on a proprietary plant-based hydrogel technology. The gel is supplied in a prefilled syringe, requires no preparation or manual pressure, and stops moderate to severe bleeding in seconds. Its human product TRAUMAGEL received FDA 510(k) clearance in August 2024 and launched nationwide in the U.S. in January 2025; its veterinary product VETIGEL has been used in roughly 65,000 procedures. The company was founded in 2010 by Joe Landolina and manufactures in a 33,000-square-foot facility in Brooklyn's Industry City.

A plant-based polymer gel that achieves hemostasis in seconds on severe hemorrhage without any preparation or manual pressure, conforming to irregular wound geometries — addressing bleeding that accounts for over 80% of operating-room deaths after major trauma and 91% of potentially survivable battlefield deaths.

Funding

  • DebtFiled Jun 26, 2026Form D/A
    $29M/ $29M
  • DebtFiled Apr 29, 2026Form D
    $5M/ $25M

Product

TRAUMAGEL

Hemostatic medical device

An FDA-cleared plant-based hemostatic gel in a prefilled syringe for the temporary external control of moderate to severe bleeding, used by EMS, trauma centers, military and law enforcement.

  • Plant-based polymer composition
  • Achieves hemostasis in seconds, including on severe hemorrhage
  • Prefilled syringe, ready to use with no preparation

Built for

Emergency medical services agencies, trauma hospitals and emergency departments, military and law enforcement, plus veterinary practices for VETIGEL

People on file